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The Journal of Immunology
Differential Production of Type I IFN Determines the
Reciprocal Levels of IL-10 and Proinflammatory Cytokines
Produced by C57BL/6 and BALB/c Macrophages
Ashleigh Howes,*,1 Christina Taubert,*,1 Simon Blankley,* Natasha Spink,†
Xuemei Wu,* Christine M. Graham,* Jiawen Zhao,‡ Margarida Saraiva,x,{
Paola Ricciardi-Castagnoli,‖ Gregory J. Bancroft,† and Anne O’Garra*,#
Pattern recognition receptors detect microbial products and induce cytokines, which shape the immunological response. IL-12,
TNF-a, and IL-1b are proinflammatory cytokines, which are essential for resistance against infection, but when produced at
high levels they may contribute to immunopathology. In contrast, IL-10 is an immunosuppressive cytokine, which dampens
proinflammatory responses, but it can also lead to defective pathogen clearance. The regulation of these cytokines is therefore central
to the generation of an effective but balanced immune response. In this study, we show that macrophages derived from C57BL/6 mice
produce low levels of IL-12, TNF-a, and IL-1b, but high levels of IL-10, in response to TLR4 and TLR2 ligands LPS and Pam3CSK4,
as well as Burkholderia pseudomallei, a Gram-negative bacterium that activates TLR2/4. In contrast, macrophages derived from
BALB/c mice show a reciprocal pattern of cytokine production. Differential production of IL-10 in B. pseudomallei and LPS-
stimulated C57BL/6 and BALB/c macrophages was due to a type I IFN and ERK1/2-dependent, but IL-27–independent, mechanism.
Enhanced type I IFN expression in LPS-stimulated C57BL/6 macrophages was accompanied by increased STAT1 and IFN regulatory
factor 3 activation. Furthermore, type I IFN contributed to differential IL-1b and IL-12 production in B. pseudomallei and LPS-
stimulated C57BL/6 and BALB/c macrophages via both IL-10–dependent and –independent mechanisms. These findings highlight key
pathways responsible for the regulation of pro- and anti-inflammatory cytokines in macrophages and reveal how they may differ
according to the genetic background of the host. The Journal of Immunology, 2016, 197: 2838–2853.
P
roinflammatory immune responses are critical in the de-
fense against pathogens; however, excessive inflammation
has the potential to cause damage to the host. Thus, immu-
noregulatory pathways controlling inflammatory cytokine production
are critical for ensuring an effective but balanced immune response
(1). Pattern recognition receptor (PRR)–activated macrophages are an
important early source of proinflammatory cytokines such as IL-12,
TNF-a, and IL-1b, and their production is modulated by a complex
array of direct and indirect regulatory mechanisms (1, 2).
A central negative regulator of inflammatory responses is the
immunosuppressive cytokine IL-10 (3). The spontaneous onset of
colitis in response to commensal gut flora in IL-10–deficient mice
(4) and enhanced susceptibility of IL-10–deficient mice to septic
shock (5) demonstrate the importance of IL-10 as a negative
feedback regulator in the immune system. IL-10 can be produced
by several cell types within the immune system, including PRR-
stimulated macrophages (6), to which IL-10 can signal back in an
autocrine manner and inhibit the production of proinflammatory
cytokines via a STAT3-dependent mechanism (7–9).
Type I IFNs constitute a group of cytokines including IFN-b and
multiple IFN-a proteins (10). Studies of the functions of type I
IFN have revealed complex immunoregulatory roles for these
cytokines. For example, type I IFN has been shown to promote
the production of IL-10 from murine macrophages (11), hu-
man monocytes (12), and human dendritic cells (13), although
the mechanisms by which this occurs are not fully understood. In
the context of proinflammatory cytokine production, the effects of
type I IFN are diverse. Mechanisms whereby type I IFN regulates
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distinct proinflammatory cytokines are as yet unclear (14–19). The
role of type I IFN in vivo in the context of infection and inflam-
mation is complex (20). Type I IFN has been shown in different
settings to contribute to control of the pathogen or, conversely,
may regulate or exacerbate inflammatory pathologies (20).
C57BL/6 and BALB/c mice differ significantly in their immune
responses, giving rise to distinct outcomes of infection, and they
have provided robust models for studying susceptibility or resis-
tance to various pathogens (21–23). Burkholderia pseudomallei is
a Gram-negative bacterium and the causative agent of melioidosis,
a major cause of sepsis and mortality in endemic regions of
Southeast Asia and Northern Australia and is increasingly being
reported across the tropics. There is no available vaccine, antibi-
otic treatment is prolonged and not always effective, and mortality
rates in acute cases can approach 50% even with optimal clinical
management (24). Both proinflammatory cytokines and IL-10 are
found at high levels in the plasma of individuals with acute in-
fection, and their concentrations can predict mortality (25). In-
fection with B. pseudomallei serves as an important clinical and
experimental example of Gram-negative sepsis, and resistance to
infection is genetically determined. Several studies have shown
that BALB/c mice, even when infected at low dose, will develop
acute disease and succumb much earlier than C57BL/6 mice,
which conversely can establish a long-term chronic infection with
this pathogen when infected with a low bacterial load (26–28).
Relative susceptibility to B. pseudomallei infection has been
correlated with distinct profiles of proinflammatory cytokines
produced by innate cells in addition to IFN-g in B. pseudomallei–
infected C57BL/6 and BALB/c mice (28–31). However, the
complexities of in vivo infection models have made it difficult to
fully dissect the mechanisms underlying differential cytokine
production between these two strains of mice. Similarly, in the
context of colitis, a disease associated with the elevated produc-
tion of several proinflammatory cytokines, IL-10–deficient BALB/
c mice are more susceptible than IL-10–deficient C57BL/6 mice
(32), but again the mechanisms underlying this phenotype are
incompletely understood. Thus, the in vitro study of cellular im-
mune responses from these mice provides a valuable comparative
model for the mechanistic dissection of cytokine regulation, which
additionally may contribute to differences in resistance of C57BL/
6 and BALB/c mice to infection and inflammatory diseases.
We report in the present study reciprocal profiles of IL-10 versus
IL-12, TNF-a, and IL-1b production from C57BL/6 and BALB/c
macrophages stimulated with B. pseudomallei and purified TLR2
and TLR4 ligands. Our investigation into these phenotypes
revealed type I IFN to be a central mediator of differential cyto-
kine production in C57BL/6 and BALB/c macrophages. Enhanced
type I IFN production accounted for the reduced levels of IL-1b
and IL-12 observed in C57BL/6 as compared with BALB/c
macrophages, by IL-10–dependent and –independent mechanisms.
We also show that prolonged IL-10 expression in C57BL/6 mac-
rophages results from type I IFN–induced ERK1/2 activation.
These results support an important immunoregulatory role for type I
IFN together with IL-10 and demonstrate that this activity is de-
pendent on the genetic background of the host.
Materials and Methods
Animals
C57BL/6 wild-type (WT), BALB/c WT, C57BL/6 Il102/2, BALB/c Il102/2,
and all other mutant mice were bred and maintained at The Francis Crick
Institute, Mill Hill Laboratory under specific pathogen-free conditions in
accordance with the Home Office, U.K., Animal Scientific Procedures Act,
1986. Tlr42/2 and Trif2/2 breeding pairs, all on a C57BL/6 background,
were provided by Prof. S. Akira (Osaka University, Osaka, Japan). C57BL/6
Ifnar12/2 breeders originated from B&K Universal (Hull, U.K.), and
C57BL/6 Tccr2/2 (referred to as Il27ra2/2 in text) breeders were provided
by Genentech (South San Francisco, CA). All mice used were females be-
tween 8 and 16 wk of age.
Generation and stimulation of bone marrow–derived
macrophages
Bone marrow–derived macrophages (BMDMs) were generated as previ-
ously described (33). On day 6, adherent cells were harvested and seeded
in 48-well tissue culture plates at 0.53 106 cells/well and rested for 18–20 h
prior to stimulation. Cells were stimulated, unless otherwise stated, with
10 ng/ml Salmonella minnesota LPS (Alexis Biochemicals), 200 ng/ml
Pam3CSK4 (InvivoGen), or heat-killed (to avoid heavy Containment Level
3 work) B. pseudomallei 576 at a ratio of 5–500 B. pseudomallei to 1
BMDM. Data were verified to be similar at the cytokine protein and mRNA
levels using live B. pseudomallei 576 (data not shown). When indicated, cells
were treated with rIFN-b (PBL) or rIL-27 (R&D Systems), both of which
were shown to have very low levels of,1 endotoxin unit/mg endotoxin only,
which on dilution in LPS-free media for assay resulted in ,0.02 endotoxin
unit/ml. Abs, 10 mg/ml anti-IFNAR1 mAb (clone MAR1-5A3, mouse IgG1;
Bio X Cell), 10 mg/ml anti–IL-10R (clone 1B1.3a, rat IgG1), or relevant
isotype control (clones GL113 or TC31.2F11, respectively) were all gifts
from DNAX Research Institute (now Merck, Palo Alto, CA). MEK inhibitor
PD184352 (1 mM) or PD0325901 (0.1 mM) and p38 inhibitor SB203580
(0.5 mM) were added to BMDMs 1 h prior or 2 h after stimulation with LPS
as indicated (34).
Cytokine quantification
Cytokines were quantified from supernatants of stimulated cells. IL-10 and
IL-12p40 were quantified by ELISA. Cone JES5-2A5 (eBioscience) was
used for IL-10 capture, and biotinylated anti-mouse IL-10 SXC-1 (BD
Biosciences) was used for detection. Clone C15.6.7 was used for IL-12p40
capture, and biotinylated anti-mouse IL-12p40 C17.8 was used for detection
(both gifts from DNAX Research Institute), followed by HRP-conjugated
streptavidin (Jackson ImmunoResearch Laboratories). IL-12p70, TNF-a,
and IL-27 (eBioscience), IL-1b (R&D Systems), and IFN-b (PBL) were
quantified using commercially available ELISA kits.
RNA isolation and quantitative real-time PCR
RNAwas harvested and isolated using anRNeasy mini kit (Qiagen) according
to the manufacturer’s instructions. cDNA was synthesized using a high-
capacity cDNA reverse transcription kit (Applied Biosystems), according
to the manufacturer’s instructions, followed by RNase H (Promega) treat-
ment for 30 min at 37˚C. Il10, Il12a, Ifnb1, Oas1g, Stat1, Stat3, Irf7, Irf9,
and Tlr4 gene expression were quantified by quantitative real-time PCR
(qRT-PCR; 7900HT; Applied Biosystems) using the TaqMan sys-
tem, and normalized to Hprt1 mRNA. Primer probes used were Il10
(Mm00439616_m1), Il12a (Mm00434165_m1), Ifnb1 (Mm00439552_s1);
Oas1g (Mm01730198_m1), Stat1 (Mm_00439518_m1), Stat3
(Mm_01219775_m1), Irf7 (Mm_00516793_g1), Irf9 (Mm_00492679_m1),
Tlr4 (Mm0045273_m1), and Hprt1 (Mm00446968_m1), all purchased from
Applied Biosystems. For the quantification of premature Il10 mRNA, the
following primers were designed using Primer Express 2.0 software and
custom made by Applied Biosystems: forward (exon 3), 59-AGCATGGC-
CCAGAAATCAAG-39; probe (exon 3), 59-CTCAGGATGCGGCTGA-39;
reverse (intron 4), 59-AGAACGCATCTGCTACTCACACA-39.
FACS staining
For FACS analysis, BMDMs were stimulated with LPS, washed, and
blocked with anti-CD16/CD32 Ab. Cells were then stained with PE-labeled
anti-mouse TLR4 (SA15-21; BioLegend) for 30 min at 4˚C and acquired
using a BD LSR II (BD Biosciences). Data were analyzed by FlowJo
software.
Microarray processing and analysis
RNA quality was confirmed (RNA integrity number, range 9–10) using an
Agilent 2100 Bioanalyzer (Agilent Technologies). RNA was prepared for
microarray analysis using the Illumina TotalPrep-96 RNA amplification kit
following the manufacturer’s instructions. cRNA (1500 ng) was hybridized
onto Illumina BeadChip arrays (MouseWG-6 v2) and scanned by an
Illumina iScan. Signal intensity calculations and background subtraction
were performed using GenomeStudio software (Illumina). Analyses of
microarray data were done using GeneSpring GX software version 12.6.1
(Agilent Technologies). A lower threshold of signal intensity was set to 10,
and the expression values were log transformed (base2) and scaled to the
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75th percentile for normalization. The expression value of each gene probe
was then normalized to the median of expression of that gene probe in all
samples. Gene probes were quality filtered for those present (p , 0.01) in
at least one sample, with 19,191 gene probes having remained. Further
statistical analysis and generation of gene lists are described in the relevant
figure legends. Canonical pathway analysis was conducted using Ingenuity
Pathway Analysis (IPA) software (Ingenuity Systems, http://www.
ingenuity.com). Expression data conform to the minimum information
about a microarray experiment standards for microarray analysis. Micro-
array data have been deposited in the Gene Expression Omnibus database
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE79809.
Determination of mRNA stability
BMDMs were stimulated with LPS, and 1 h later 10 mg/ml actinomycin D
(Streptomyces sp., Sigma-Aldrich) was added (t = 0) to the cultures.
mRNA was harvested after 30, 60, or 90 min, reverse transcribed into
cDNA, and quantified by qRT-PCR.
Quantification of IFN regulator factor 3 activation
Nuclear extracts of 2 h heat-killed B. pseudomallei–stimulated BMDMs
(5:1 B. pseudomallei/BMDM) were prepared with the Nuclear Extract Kit
and assayed with the TransAM IFN regulatory factor (IRF) 3 kit (both
from Active Motif) according to the manufacturer’s instructions.
Western blotting
BMDMs were rested in 1% FCS for 20 h prior to stimulation with LPS or
rIFN-b. At the indicated time points cells were washed with PBS and lysed
in RIPA buffer as previously described (35) or in Triton X-100 lysis buffer
(for IRF3 Western blots). Proteins were resolved on a 12.5% SDS-
polyacrylamide gel and transferred to polyvinylidene difluoride membranes
(Millipore). Membranes were probed with Abs against phospho-ERK1/2
(T185/Y187), total ERK1/2 (both Invitrogen), phospho-p38 (T180/Y182),
total p38, phospho-STAT1 (Y701), total STAT1, phospho-IRF3 (S396,
4D4G) (Cell Signaling Technology), total IRF3, GAPDH (FL-335), heat
shock protein 90a/b (H-114) (Santa Cruz Biotechnology), or actin (Calbio-
chem) followed by HRP-conjugated goat anti-rabbit IgG, rabbit anti-goat IgG
(SouthernBiotech), or goat anti-mouse IgM (Calbiochem), and visualized
using Pierce ECLWestern blotting substrate (Thermo Scientific) or Luminata
Crescendo Western chemiluminescent HRP substrate (Millipore). Western
blots were quantified using Quantity One software.
Statistical analysis
GraphPad Prism software was used to analyze data by one- or two-way
ANOVA with Bonferroni multiple comparison testing or a Student t test.
Statistical analyses of microarray data were done using GeneSpring GX
software version 12.6.1 (Agilent Technologies) and are described in the
relevant figure legends.
Results
B. pseudomallei, LPS, and Pam3CSK4 induce higher levels
of IL-10 but lower levels of proinflammatory cytokines in
C57BL/6 compared with BALB/c macrophages
To better understand the factors regulating the production of pro- and
anti-inflammatory cytokines in innate immune cells, we investigated
TLR-induced IL-10, IL-12, TNF-a, and IL-1b production from
C57BL/6 and BALB/c macrophages. C57BL/6 and BALB/c macro-
phages were stimulated over a time course with either B. pseudomallei,
which activates both TLR2 and TLR4 signaling (36–38), or purified
TLR2 and TLR4 ligands Pam3CSK4 and LPS, respectively (Fig. 1).
Significantly higher levels of IL-10 were produced by C57BL/6 as
compared with BALB/c macrophages with all three stimuli across the
time course of stimulation (Fig. 1A). IL-12 is a heterodimeric cytokine
composed of IL-12p40 and IL-12p35 subunits, which generate the
biologically active IL-12p70 (39). In contrast to IL-10, levels of
IL-12p40 production were higher in B. pseudomallei– and LPS-
stimulated BALB/c compared with C57BL/6 macrophages (Fig. 1B).
However, the levels of IL-12p40 production were marginally higher in
C57BL/6 macrophages stimulated with Pam3CSK4 (Fig. 1B). The
expression of Il12a mRNA (which encodes the IL-12p35 subunit) was
significantly higher in BALB/c compared with C57BL/6 macrophages
stimulated with B. pseudomallei, LPS, or Pam3CSK4 (Fig. 1B).
Consistent with this, the level of IL-12p70 production was significantly
higher in B. pseudomallei–stimulated BALB/c compared with C57BL/
6 macrophages (Fig. 1B), although generally below the limit of de-
tection in LPS- or Pam3CSK4-stimulated cells. We also observed
higher levels of TNF-a (Fig. 1C) and IL-1b (Fig. 1D) production from
BALB/c compared with C57BL/6 macrophages across the time course
of B. pseudomallei, LPS, and Pam3CSK4 stimulation. Elevated levels
of IL-10 but lower proinflammatory cytokine production were also
observed in C57BL/6 relative to BALB/c macrophages when stimu-
lated with a range of doses of B. pseudomallei, LPS, and Pam3CSK4
(Supplemental Fig. 1).
IL-10 has the ability to suppress proinflammatory cytokine
production from macrophages (3). To investigate whether the low
levels of IL-12, TNF-a, and IL-1b production from C57BL/6
compared with BALB/c macrophages were due to the much
higher levels of IL-10 produced by C57BL/6 macrophages,
B. pseudomallei–, LPS-, and Pam3CSK4-stimulated C57BL/6
Il102/2 and BALB/c Il102/2 macrophages were assessed for
their levels of IL-12p70, TNF-a, and IL-1b production
(Supplemental Fig. 2). IL-12p70 production was found to be
greatly increased in Il102/2 macrophages relative to WT cells
from both strains of mice; however, the levels remained higher
in BALB/c compared with C57BL/6 macrophages in response to
B. pseudomallei or LPS stimulation (Supplemental Fig. 2A). In
Pam3CSK4-stimulated cells, the increase in IL-12p70 production
in IL-10–deficient cells compared with WTwas modest, although the
levels of IL-12p70 production were the same in C57BL/6 Il102/2
and BALB/c Il102/2 macrophages (Supplemental Fig. 2A). In con-
trast, TNF-a production was equivalent in B. pseudomallei–, LPS-,
and Pam3CSK4-stimulated C57BL/6 Il102/2 and BALB/c Il102/2
macrophages (Supplemental Fig. 2B). IL-1b production remained
higher in B. pseudomallei– and LPS-stimulated BALB/c Il102/2
compared with C57BL/6 Il102/2 macrophages, but it was more
comparable in Pam3CSK4-stimulated cells (Supplemental Fig. 2C).
Thus, the differential production of TNF-a by all stimuli, as well as
the differences in Pam3CSK4-induced IL-12p70 and IL-1b, was
largely explained by IL-10–mediated inhibition. However, the dif-
ferential production of IL-12p70 and IL-1b in B. pseudomallei– and
LPS-stimulated C57BL/6 and BALB/c macrophages, although it
may in part be explained by IL-10, was still observed in the complete
absence of IL-10, suggesting an additional mechanism of inhibition
in C57BL/6 macrophages. Additionally, the factors contributing to
the differential production of IL-10 itself in C57BL/6 and BALB/c
macrophages remained unclear.
B. pseudomallei–stimulated C57BL/6 macrophages express
higher levels of type I IFN pathway–related genes compared
with BALB/c macrophages
To investigate further the potential mechanisms underlying differ-
ential production of IL-10 and proinflammatory cytokines by TLR4-
stimulated C57BL/6 and BALB/c macrophages, we first undertook
experiments to address whether this was attributable to differential
TLR4 expression or early signaling events downstream of this re-
ceptor. Steady-state Tlr4 mRNA expression, TLR4 surface expres-
sion, and TLR4 endocytosis post-LPS stimulation were the same in
C57BL/6 and BALB/c macrophages (Fig. 2A, 2B). Early activation
of the MAPKs ERK1/2 or p38 by LPS was also similar in C57BL/6
and BALB/c macrophages (Fig. 2C). These data suggest that the
differential cytokine production in BALB/c versus C57BL/6 mac-
rophages was not simply due to differential TLR abundance or
immediate signaling downstream of TLR4.
We therefore undertook an unbiased microarray analysis of these
cells stimulated with B. pseudomallei for 3 and 6 h. At 3 h, 790
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genes were found to be differentially regulated by B. pseudomallei
in C57BL/6 and BALB/c macrophages (Fig. 2D). Most of these
genes were upregulated by B. pseudomallei stimulation in both
strains of mice, and of these almost all were more strongly up-
regulated in C57BL/6 compared with BALB/c macrophages. The
genes downregulated by B. pseudomallei stimulation in C57BL/6
macrophages were also downregulated in BALB/c macrophages,
although either more strongly or more weakly in comparison. At
6 h, 2246 genes were found to be differentially regulated by
B. pseudomallei in C57BL/6 and BALB/c macrophages (Fig. 2D),
suggesting a reinforcement of differential gene expression over
time. These genes included those up- and downregulated by
B. pseudomallei stimulation and, in contrast to the 3 h time point,
were either more strongly or weakly induced in BALB/c macro-
phages, resulting in a complex profile of gene expression
(Fig. 2D). Of note, Il10 (BALB/c low, gray dot highlighted red in
FIGURE 1. C57BL/6 macrophages produce higher levels of IL-10 but lower levels of proinflammatory cytokines compared with BALB/c macrophages
in response to bacterial products. C57BL/6 and BALB/c BMDMs were stimulated with B. pseudomallei, LPS, or Pam3CSK4 for the indicated times. IL-10
(A), IL-12p40, IL-12p70 (B), TNF-a (C), and IL-1b (D) protein levels in supernatants were determined by ELISA. Il12a mRNA expression (B) was
determined by qRT-PCR and normalized to Hprt1 mRNA expression. Graphs show means 6 SEM of three independent experiments. *p , 0.05, **p ,
0.01, ***p , 0.001 as determined by two-way ANOVA (Bonferroni multiple comparison test). Bps, B. pseudomallei.
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FIGURE 2. C57BL/6 macrophages show similar early TLR4-induced responses but higher expression of type I IFN pathway genes, as compared with
BALB/c macrophages. (A) Tlr4 mRNA expression in C57BL/6 and BALB/c BMDMs at steady-state was determined by qRT-PCR and normalized to Hprt1
mRNA expression. (B) C57BL/6 and BALB/c BMDMs were stimulated with LPS for the indicated times and TLR4 expression was analyzed by flow
cytometry. (C) BMDMs were stimulated with LPS as indicated, and phosphorylation of ERK1/2 and p38 in whole-cell lysates was determined by Western
blotting. (D and E) C57BL/6 and BALB/c BMDMs were stimulated with B. pseudomallei for 3 or 6 h in triplicate cultures. Total RNA was isolated and
processed for microarray analysis as described in Materials and Methods. (D) Genes significantly differentially regulated by B. pseudomallei in C57BL/6
and BALB/c BMDMs were identified by two-way ANOVA analysis (p , 0.01, Benjamini–Hochberg false discovery rate) and the selection of genes that
were significantly different due to both stimulation and strain. Genes significantly changed due to stimulus alone or strain alone were excluded from the
analysis. Expression level of individual genes (black dots, C57BL/6; gray dots, BALB/c) are shown as log2 fold change over corresponding media control
samples and ordered according to their C57BL/6 expression level. (E) Top 10 IPA pathways significantly associated with the (Figure legend continues)
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Fig. 2D, 6 h after stimulation), Il12a, and Tnf (BALB/c high, gray
dots highlighted red in Fig. 2D, 6 h after stimulation) were found
to be present at similar relative levels between BALB/c and
C57BL/6 macrophages, as observed at the protein level (Fig. 1).
IL-1b was not found to be significantly differentially expressed at
the mRNA level, suggesting that this cytokine may be differen-
tially regulated posttranscriptionally in C57BL/6 and BALB/c
macrophages.
To better understand the biological relationships between the
differentially regulated genes, transcripts identified at 3 and 6 h
were subjected to canonical pathway analysis (IPA). Among the top
10 pathways significantly associated with the gene lists at each time
point, several were found to relate to type I IFN–mediated
processes. These included IFN signaling, JAK/STAT signaling,
activation of IRF by cytosolic PRRs, and role of JAK1, JAK2,
TYK2 in IFN signaling at 3 h, and activation of IRF by cytosolic
PRRs, role of PKR in IFN induction and antiviral response, and
IFN signaling at 6 h (Fig. 2E, Supplemental Table I). Most of the
differentially regulated genes within these type I IFN–related
pathways, including Oas1g, Stat1, Stat3, Irf7, and Isgf3g (IRF9),
were more highly expressed in C57BL/6 macrophages
(Supplemental Table I), and this was validated by qRT-PCR (Fig.
2F). Additionally, the dominance of the IFN-inducible signaling
pathway genes in C57BL/6 versus BALB/c macrophages was val-
idated in an independent experiment using live B. pseudomallei
(data not shown). These data suggest that enhanced type I IFN
signaling in C57BL/6 compared with BALB/c macrophages may be
a fundamental difference in the responses of these cells to
B. pseudomallei and may explain their differential expression of
IL-10 versus proinflammatory cytokines.
BALB/c macrophages show reduced IFN-b production and
STAT1 and IRF3 activation compared with C57BL/6
macrophages upon TLR4 stimulation
In keeping with higher expression of type I IFN–inducible
genes in C57BL/6 macrophages as shown by our microarray
analysis (Fig. 2), Ifnb1 mRNAwas more highly expressed in B.
pseudomallei– and LPS-stimulated C57BL/6 macrophages com-
pared with BALB/c macrophages (Fig. 3A). In both strains, Ifnb1
mRNA expression peaked at 1 h, returning to near baseline levels
by 6 h, explaining why in the microarray analysis, which was
conducted at later time points, Ifnb1 itself was not identified as
a C57BL/6-high gene (Supplemental Table I). Protein levels of
IFN-b production, which peaked at 3 h, were also higher in
B. pseudomallei– and LPS-stimulated C57BL/6 compared with
BALB/c macrophages (Fig. 3B). We additionally assessed the
phosphorylation of STAT1, activated downstream of the type I IFN
receptor, in LPS-stimulated C57BL/6, BALB/c, and C57BL/6
Ifnar12/2 macrophages (Fig. 3C, 3D). STAT1 was phosphorylated
in macrophages from both strains of mice but was reduced in
BALB/c macrophages compared with C57BL/6 after 2 h of stim-
ulation. Thus, the level of type I IFN produced by BALB/c mac-
rophages is sufficient to activate STAT1, but not to the level seen in
C57BL/6 macrophages. The total absence of STAT1 phosphoryla-
tion in LPS-stimulated C57BL/6 Ifnar12/2 macrophages confirmed
that the STAT1 activation in WT macrophages was due to type I
IFN signaling (Fig. 3C, 3D).
To investigate the mechanism by which B. pseudomallei induces
IFN-b production, C57BL/6 Trif2/2 and C57BL/6 Tlr42/2 mac-
rophages were assessed for their production of IFN-b in response
to B. pseudomallei or LPS (Fig. 3E). In the absence of TRIF or
TLR4, neither B. pseudomallei nor LPS was able to induce IFN-b
production, suggesting that differential production of this cytokine
in B. pseudomallei– or LPS-stimulated C57BL/6 and BALB/c
macrophages may be a result of differential activation of the
TLR4/TRIF pathway. In support of this, the activation of IRF3,
which is required for IFN-b production downstream of TLR4 (40),
was lower in B. pseudomallei–stimulated BALB/c macrophages
(Fig. 3F–H).
Type I IFN signaling mediates the higher level of IL-10
production observed in B. pseudomallei– and LPS-stimulated
C57BL/6 compared with BALB/c macrophages
Type I IFN has been reported to positively regulate IL-10 pro-
duction in macrophages stimulated with LPS or infected with
bacteria such as Listeria monocytogenes or Mycobacterium tu-
berculosis (11, 16, 33, 41, 42). To determine whether autocrine
type I IFN signaling mediated the higher level of IL-10 production
in C57BL/6 compared with BALB/c macrophages, C57BL/6
Ifnar12/2 macrophages were stimulated with B. pseudomallei or
LPS over a time course. The level of IL-10 production was sig-
nificantly reduced in C57BL/6 Ifnar12/2 macrophages compared
with C57BL/6 WT macrophages, and it was reduced to the level
of IL-10 produced by BALB/c macrophages (Fig. 4A). Microarray
analysis of C57BL/6 WT, BALB/c, and C57BL/6 Ifnar12/2
macrophages stimulated with B. pseudomallei for 6 h revealed
lower expression of Il10 mRNA and IL-10 pathway genes, in-
cluding Stat3, Jak1, Ccr5, Il4ra, and Arg2, in BALB/c and
C57BL/6 Ifnar12/2 macrophages relative to C57BL/6 WT mac-
rophages (Fig. 4B). These data support a role for type I IFN in the
differential regulation of IL-10 in B. pseudomallei– and LPS-
stimulated C57BL/6 and BALB/c macrophages.
Type I IFN signaling promotes IL-10 through active
transcription and stabilization of Il10 mRNA
To investigate the mechanisms by which type I IFN promotes IL-10
production in C57BL/6 macrophages, a detailed time course of Il10
mRNA kinetics was carried out on B. pseudomallei– and LPS-
stimulated C57BL/6 WT, BALB/c, and C57BL/6 Ifnar12/2
macrophages. B. pseudomallei– and LPS-stimulated C57BL/6 WT
macrophages expressed an initial Il10 mRNA peak at 0.5 h fol-
lowed by a second peak at 4 h (Fig. 5A). BALB/c macrophages
expressed the initial peak of Il10 mRNA, although at a lower
magnitude relative to C57BL/6 WT macrophages; however, they
completely lacked the second peak of Il10 mRNA (Fig. 5A). In
C57BL/6 Ifnar12/2 macrophages, although the first peak of Il10
mRNA was mostly unaffected by the absence of type I IFN sig-
naling, the second peak was completely abrogated (Fig. 5A). This
suggests that autocrine type I IFN activates a late transcriptional
wave of Il10 mRNA expression, supported by the presence of a
second peak of premature Il10 mRNA, indicative of active tran-
scription, in LPS-stimulated C57BL/6 but not BALB/c macro-
phages (Fig. 5B). Additionally, whereas in BALB/c and C57BL/6
Ifnar12/2 macrophages a rapid decay of the Il10 mRNA is observed
genes differentially regulated by B. pseudomallei stimulation in C57BL/6 and BALB/c macrophages at each time point are shown. The x-axis represents the
percentage overlap between input genes and annotated genes within the pathway. Colors within bars denote genes that are more highly expressed in C57BL/6 or
BALB/c macrophages. Benjamini–Hochberg (B-H) corrected 2log(p value) represents pathway association. *Type I IFN–related pathway. (F) C57BL/6 and
BALB/c BMDMs were stimulated with B. pseudomallei for 6 h. Gene expression was determined by qRT-PCR and expression values were normalized to Hprt1
mRNA expression. All graphs show means 6 SEM of three independent experiments. Western blot (C) is representative of two independent experiments.*p ,
0.05, **p , 0.01, ***p , 0.001 as determined by two-way ANOVA (Bonferroni multiple comparison test).
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FIGURE 3. TLR4-dependent IFN-b production and STAT1 and IRF3 activation are higher in C57BL/6 compared with BALB/c macrophages. BMDMs
were stimulated with B. pseudomallei or LPS for the indicated times. (A) Ifnb1 mRNA expression was determined by qRT-PCR and normalized to Hprt1
mRNA expression. (B) IFN-b production was quantified by ELISA. (C) Whole-protein extracts were generated and analyzed by Western blot for total and
phosphorylated STAT1, and actin loading control. (D) Relative intensity of two independent experiments shown for data represented in (C). (E) IFN-b
production was quantified by ELISA. (F) C57BL/6 and BALB/c macrophages were stimulated with B. pseudomallei for 2 h, and nuclear extracts were
analyzed for active IRF3 by ELISA. (G) Whole-protein extracts were generated and analyzed by Western blot for total and phosphorylated IRF3 and heat
shock protein 90 loading control. (H) Relative intensity of three independent experiments shown from data in (G). Graphs show means 6 SEM of two to
four (E) or at least three independent experiments (A and B). *p, 0.05, **p, 0.01, ***p, 0.001 as determined by two-way ANOVA (Bonferroni multiple
comparison test).
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FIGURE 4. B. pseudomallei– and LPS-stimulated C57BL/6 Ifnar12/2 and BALB/c macrophages have similar levels of IL-10 production and show
reduced expression of IL-10 pathway genes compared with C57BL/6 WT macrophages. (A) C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 BMDMs were
stimulated with B. pseudomallei or LPS for the indicated times. IL-10 production was quantified by ELISA. Graphs show means 6 SEM of four inde-
pendent experiments. **p , 0.01, ***p , 0.001 as determined by two-way ANOVA (*C57BL/6 versus BALB/c; +C57BL/6 versus C57BL/6 Ifnar12/2),
Bonferroni multiple comparison test. (B) C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 BMDMs were stimulated with B. pseudomallei for 6 h in triplicate
cultures. Total RNAwas isolated and processed for microarray analysis as described in Materials and Methods. Normalized expression of genes annotated
within the IL-10 pathway (IPA) is shown hierarchically clustered according to expression. Lower panel shows overlay of gene expression level (red high,
blue low) on a schematic of the IL-10 pathway (IPA).
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after 0.5 h, in C57BL/6 macrophages this decay is much less pro-
nounced (Fig. 5A). Thus, we further investigated whether there was
an additional effect of type I IFN on Il10 mRNA stability. We ob-
served reduced Il10 mRNA stability in C57BL/6 Ifnar12/2 macro-
phages compared with C57BL/6 WT macrophages, demonstrating
that autocrine type I IFN also has a stabilizing effect on Il10 mRNA
(Fig. 5C).
It has been reported that in LPS-stimulated macrophages, type I
IFN–induced IL-27 is required for the optimal enhancement of IL-10
by type I IFN (43). However, others have shown that murine mac-
rophages stimulated with LPS are unresponsive to IL-27 (44). To
investigate whether the type I IFN–mediated enhancement of IL-10
production in C57BL/6 WT macrophages is dependent on IL-27,
C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 macrophages were
stimulated with B. pseudomallei or LPS and IL-27 production was
determined (Supplemental Fig. 3A). In response to both stimuli, the
overall magnitude of IL-27 production was similar in C57BL/6 and
BALB/c macrophages. In C57BL/6 Ifnar12/2 macrophages, IL-27
production was drastically reduced (Supplemental Fig. 3A), in
agreement with previous studies (45) showing a role for type I IFN
in the promotion of IL-27 in C57BL/6 macrophages. However,
B. pseudomallei– and LPS-stimulated C57BL/6 Il27ra2/2 macro-
phages revealed no significant difference in IL-10 production as
compared with WT macrophages (Supplemental Fig. 3B). Addi-
tionally, IL-10 production was similarly enhanced by addition of
exogenous IFN-b in WT C57BL/6 and C57BL/6 Il27ra2/2
macrophages (Supplemental Fig. 3C). Furthermore, the addition
of exogenous IL-27 did not enhance IL-10 production by LPS-
stimulated C57BL/6, BALB/c, or C57BL/6 Ifnar12/2 macro-
phages (Supplemental Fig. 3D). These data demonstrate that type
I IFN–mediated enhancement of IL-10 in B. pseudomallei– and
LPS-stimulated C57BL/6 macrophages is independent of IL-27.
FIGURE 5. Type I IFN promotes B. pseudomallei– and LPS-stimulated IL-10 production transcriptionally and by stabilization of Il10 mRNA in C57BL/6
and BALB/c macrophages. (A and B) C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 BMDMs were stimulated with B. pseudomallei or LPS for the indicated
times. (C) C57BL/6 and C57BL/6 Ifnar12/2 BMDMs were stimulated with LPS for 1 h and treated with actinomycin D (ActD). (A–C) Il10 mRNA was
harvested and quantified by qRT-PCR, normalized to Hprt1 mRNA levels. (D) C57BL/6 and BALB/c BMDMs were treated with 2 or 20 ng/ml IFN-b for 2 h
prior to stimulation with B. pseudomallei or LPS for 24 h. IL-10 production was quantified by ELISA. Graphs show means6 SEM of two to three independent
experiments. *p , 0.05, **p , 0.01, ***p , 0.001 by two-way ANOVA (*C57BL/6 versus BALB/c, +C57BL/6 versus C57BL/6 Ifnar12/2), Bonferroni
multiple comparison test.
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Addition of type I IFN enhances IL-10 production in both
C57BL/6 and BALB/c macrophages stimulated with
B. pseudomallei and LPS
To test whether the addition of type I IFN could enhance IL-10
production in BALB/c macrophages and potentially rescue IL-10
production in this strain, we treated C57BL/6 and BALB/c mac-
rophages with exogenous IFN-b in the presence or absence of PRR
ligation by B. pseudomallei or LPS (Fig. 5D). Treatment with IFN-b
in the absence of PRR stimulation did not induce IL-10 production
from C57BL/6 or BALB/c macrophages. In B. pseudomallei–stimulated
cells, the addition of IFN-b greatly enhanced IL-10 production in
C57BL/6 and BALB/c macrophages; however, IL-10 production
remained significantly higher in C57BL/6 macrophages (Fig. 5D). In
LPS-stimulated macrophages, the addition of IFN-b also enhanced
IL-10 production in both C57BL/6 and BALB/c macrophages
(Fig. 5D). Furthermore, upon treatment with IFN-b, the levels of
LPS-induced IL-10 from BALB/c macrophages were as high as
those from C57BL/6 macrophages (Fig. 5D). BALB/c macrophages
therefore have the capacity to produce enhanced levels of IL-10 in
response to IFN-b treatment. Furthermore, in LPS-stimulated cells,
IFN-b had the potential to fully restore IL-10 production to the level
observed in similarly stimulated C57BL/6 macrophages.
Type I IFN stimulates IL-10 production in C57BL/6
macrophages through the activation of ERK1/2 MAPK
Our data suggest that type I IFN is an important factor in driving the
differential production of IL-10 in C57BL/6 and BALB/c macro-
phages; however, how type I IFN regulates IL-10 production in
macrophages is incompletely understood. ERK1/2 and p38 MAPKs
are central regulators of IL-10 in TLR-stimulated C57BL/6 mac-
rophages (reviewed in Ref. 46). We compared the contribution of
these MAPKs to IL-10 production in C57BL/6 and BALB/c mac-
rophages by incubating the cells with p38 and MEK1/2 (upstream of
ERK1/2) inhibitors. In keeping with previous studies reviewed in
Gabrysova´ et al. (46), we observed reduced IL-10 production in
LPS-stimulated C57BL/6 macrophages upon inhibition of p38 or
ERK1/2 signaling (Fig. 6A). IL-10 production was further reduced
when p38 and ERK1/2 activation was concomitantly blocked
(Fig. 6A). In BALB/c macrophages, however, IL-10 production was
almost completely abrogated by inhibition of p38 signaling alone,
but it was not affected by ERK1/2 inhibition (Fig. 6A). Similarly, in
LPS-stimulated C57BL/6 Ifnar12/2 macrophages, inhibition of p38
signaling significantly reduced IL-10 production, whereas ERK1/2
inhibition had no effect (Fig. 6B). This implied a role for ERK1/2 in
the regulation of IL-10 only in the presence of type I IFN. Sup-
porting this, ERK1/2 phosphorylation was induced in C57BL/6 and
BALB/c macrophages upon treatment with recombinant IFN-b and
this was not observed in C57BL/6 Ifnar12/2 macrophages, dem-
onstrating the specificity of the IFN-b activation of ERK1/2
(Fig. 6C) and that this was not through activation of any PRR. To
formally establish the role of p38 and ERK1/2 in the regulation of
IL-10 by type I IFN, we inhibited these MAPKs 1 h before or 2 h
after LPS stimulation, with the latter time point representing the
peak of autocrine type I IFN signaling (Fig. 3C). Inhibition of p38
prior to LPS stimulation led to a decrease in Il10 mRNA expression
at all time points; however, the type I IFN–dependent second peak of
Il10 mRNA remained present (Fig. 6D). Inhibition of p38 at 2 h
poststimulation had no significant effect on Il10 mRNA levels
(Fig. 6D). Inhibition of ERK1/2 signaling at either time point had no
effect on the first peak of Il10 mRNA, whereas it completely
blocked the second peak of Il10 mRNA transcription (Fig. 6E). This
result was confirmed using an additional structurally unrelated yet
specific MEK1/2 inhibitor (trametinib [from Selleck Chemicals],
data not shown). These findings demonstrate a requirement for
ERK1/2 in the induction of Il10mRNA expression by autocrine type
I IFN in C57BL/6 macrophages.
Reduced levels of IL-1b and IL-12 production observed in
C57BL/6 as compared with BALB/c macrophages result from
type I IFN action through IL-10–dependent and –independent
mechanisms
Because IL-10–mediated inhibition did not fully account for dif-
ferential IL-1b production in B. pseudomallei– or LPS-stimulated
C57BL/6 and BALB/c macrophages (Supplemental Fig. 2C), we
sought to investigate whether type I IFN had an additional effect
on the regulation of IL-1b in these cells. Assessment of IL-1b
production in B. pseudomallei– and LPS-stimulated C57BL/6
Ifnar12/2 macrophages revealed significantly elevated IL-1b
production relative to C57BL/6 WT macrophages, to levels sim-
ilar to BALB/c macrophages (Fig. 7A). Indeed, the addition of
exogenous IFN-b significantly reduced IL-1b production in both
C57BL/6 and BALB/c macrophages, supporting a role for type I
IFN in the negative regulation of IL-1b in this system (Fig. 7B).
To determine whether type I IFN could negatively regulate IL-1b
production through mechanisms other than through the promotion
of IL-10 as previously reported (14, 16, 42), IL-1b production was
assessed from C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 mac-
rophages stimulated with B. pseudomallei or LPS in the presence
of a blocking Ab against the IL-10 receptor (anti-IL-10R) or
isotype control Ab (Fig. 7C). The blockade of IL-10 signaling
enhanced IL-1b production in all cell types. However, in the
presence of anti–IL-10R, IL-1b production was highly elevated in
C57BL/6 Ifnar12/2 macrophages relative to C57BL/6 WT and
even BALB/c macrophages (Fig. 7C). Thus, the loss of type I IFN
signaling can enhance IL-1b production in the absence of IL-10
signaling, supporting a role for IL-10–independent inhibition of
IL-1b production by type I IFN in B. pseudomallei– and LPS-
stimulated C57BL/6 macrophages. The production of TNF-a
in C57BL/6 Ifnar12/2 macrophages was enhanced relative to
C57BL/6 WT in the context of B. pseudomallei stimulation, but it
was not affected in LPS-stimulated macrophages, implying
stimulus-specific regulation of this cytokine by type I IFN
(Supplemental Fig. 3E).
Type I IFN has been reported to modulate the levels of IL-12
production in various contexts (15, 16, 18, 19, 33). We observed
that IL-12p70 production and Il12a expression levels were not
different in B. pseudomallei– and LPS-stimulated C57BL/6
Ifnar12/2 macrophages as compared with C57BL/6 WT macro-
phages (Fig. 8A, 8B). However, the addition of IFN-b abrogated
the production of IL-12p70 from B. pseudomallei–stimulated cells
(no IL-12p70 was detected in LPS-stimulated cells), even in
BALB/c macrophages, suggesting that type I IFN does have the
capacity to inhibit IL-12p70 production in this system (Fig. 8C).
We considered that residual IL-10 production in C57BL/6
Ifnar12/2 macrophages was preventing the induction of high
levels of IL-12p70 production; however, even in the presence of
anti–IL-10R, IL-12p70 production was equivalent in C57BL/6
Ifnar12/2 macrophages compared with C57BL/6 WT macro-
phages stimulated with B. pseudomallei or LPS (Fig. 8D).
Despite a negative regulatory effect of exogenous IFN-b ad-
dition on the production of IL-12p70 (Fig. 8C), previous studies
have indicated that low-level basal IFN-b production, which
gives rise to tonic type I IFN signaling, is required for optimal
IL-12 production from innate cells (16, 18). As tonic type I IFN
signaling is absent from C57BL/6 Ifnar12/2 macrophages, we
postulated that this may contribute to poor IL-12p70 production,
even in the absence of IL-10 signaling (Fig. 8D). Thus, to uncouple
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tonic type I IFN signaling from PRR-induced autocrine type I IFN
signaling, we treated WT C57BL/6 and BALB/c macrophages with
anti-IFNAR1 in the presence and absence of anti–IL-10R mAbs
(Fig. 8E). Upon treatment with anti-IFNAR1, no effect was ob-
served on IL-12p70 production from B. pseudomallei– or LPS-
stimulated C57BL/6 macrophages; however, a small increase in
IL-12p70 production was observed in BALB/c macrophages
(Fig. 8E, inset).
As expected, treatment with anti–IL-10R mAbs significantly
increased IL-12p70 production in macrophages from both strains
of mice, but IL-12p70 remained higher in BALB/c macrophages.
In C57BL/6 macrophages, anti-IFNAR1 treatment in the presence
of anti–IL-10R significantly increased IL-12p70 levels relative to
anti–IL-10R treatment alone. In contrast, anti-IFNAR1 plus anti–
IL-10R mAb–treated BALB/c macrophages did not further en-
hance IL-12p70 production. Importantly, the level of IL-12p70
production from anti-IFNAR1/anti–IL-10R–treated C57BL/6 and
BALB/c macrophages were comparable. Similar results were
obtained by treating C57BL/6 Il102/2 and BALB/c Il102/2
macrophages with anti-IFNAR1 (Supplemental Fig. 3F). These
findings demonstrate that deficient IL-12p70 production from
C57BL/6 macrophages can be rescued by the elimination of both
PRR-induced IL-10 and type I IFN signaling.
Discussion
The balance of pro- and anti-inflammatory immune responses is
essential to ensure effective but safe pathogen clearance. C57BL/6
and BALB/c mice differ significantly in their immune responses
during infections and inflammatory diseases (21, 23, 32). A clear
example of this is the B. pseudomallei infection model where
C57BL/6 mice have enhanced resistance compared with BALB/c
mice (26–28). The higher production of proinflammatory cyto-
kines in BALB/c mice has been associated with exacerbated B.
pseudomallei–induced pathology (28–30). However, it is unclear
whether this exacerbated pathology is contributed to by decreased
control of the pathogen, or by an inability to induce a regulated
response. In in vivo settings, signals from multiple cell types are
integrated to induce a balanced production of proinflammatory
versus anti-inflammatory cytokines such as IL-10 to control
pathogens with minimum host damage. This complexity makes
the clear dissection of these mechanisms prohibitive in in vivo
models. We report in this study, using an in vitro model that al-
lows the examination of these complex phenotypes, that C57BL/6
macrophages produced higher levels of IL-10 but lower levels of
TNF-a, IL-12p70, and IL-1b compared with BALB/c macro-
phages when stimulated with the bacterium B. pseudomallei, LPS,
or Pam3CSK4. We reveal a central role for autocrine type I IFN in
FIGURE 6. Type I IFN stimulates IL-10 pro-
duction in C57BL/6 macrophages through the
activation of ERK1/2 MAPK. (A) C57BL/6 and
BALB/c BMDMs were treated with PD184352
and/or SB203580 or DMSO as control 1 h prior
to stimulation with LPS for 24 h. IL-10 pro-
duction was quantified by ELISA. (B) C57BL/6
WT and Ifnar2/2 BMDMs were treated with
PD0325901 or SB203580 or DMSO as control
1 h prior to stimulation with LPS for 24 h. IL-10
production was quantified by ELISA. (C)
C57BL/6 WT, Ifnar12/2, and BALB/c BMDMs
were stimulated with 20 ng/ml IFN-b. Whole-
protein extracts were generated and analyzed
by Western blot for total and phosphorylated
ERK1/2 and GAPDH as loading control. (D and
E) C57BL/6 and BALB/c WT BMDMs were
treated with SB203580 or PD0325901 1 h prior
to or 2 h after stimulation with LPS. Il10 mRNA
was harvested at indicated times and quantified
by qRT-PCR, normalized to Hprt1mRNA levels.
Graphs show means 6 SEM of three to five in-
dependent experiments. Western blot shown is
representative of three independent experiments.
*p , 0.05, **p , 0.01, ***p , 0.001, ns indi-
cates nonsignificant as determined by one-way
(A) or two-way ANOVA analysis (Bonferroni
multiple comparison test) (B, D, and E).
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the increased production of IL-10 and increased Il10 mRNA sta-
bility by C57BL/6 macrophages, which is accompanied by increased
STAT1 and IRF3 activation. The enhanced and prolonged expression
of Il10 was dependent on type I IFN–induced late ERK1/2 phos-
phorylation. Conversely, type I IFN suppressed the production of the
proinflammatory cytokines IL-12 and IL-1b via IL-10–dependent
and –independent mechanisms in B. pseudomallei– and LPS-
stimulated C57BL/6 macrophages. These findings demonstrate that
fundamental differences in type I IFN induction and function in
C57BL/6 and BALB/c macrophage responses may contribute to
their differential phenotypes.
The differential production of cytokines by macrophages from
both mouse strains was not due to different levels of Tlr4 mRNA
expression or protein production, and this was corroborated by
similar levels of early p38 and ERK1/2 activation following LPS
stimulation. A comparative microarray analysis of temporal gene
expression in B. pseudomallei–stimulated C57BL/6 and BALB/c
macrophages revealed major differences in gene expression, with 790
genes being differentially expressed after 3 h, and strikingly 2246
genes being differentially expressed after 6 h poststimulation. This
microarray analysis revealed an unexpected higher expression of type
I IFN–responsive genes and type I IFN pathway genes in C57BL/6
macrophages, including Oas1g, Stat1, Stat3, Irf7, and Irf9. This
corresponded with higher IFN-b production in B. pseudomallei– and
LPS-stimulated C57BL/6 macrophages. Our findings that B. pseu-
domallei–induced IFN-b production was dependent on TLR4 and
FIGURE 7. IL-1b production is inhibited in B. pseudomallei– and LPS-stimulated C57BL/6 macrophages by type I IFN through IL-10–dependent and
–independent mechanisms. (A) C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 BMDMs were stimulated with B. pseudomallei or LPS for the indicated times.
(B) C57BL/6 and BALB/c BMDMs were treated with 2 or 20 ng/ml IFN-b for 2 h prior to stimulation with B. pseudomallei or LPS for 24 h. (C) C57BL/6,
BALB/c, and C57BL/6 Ifnar12/2 BMDMs were stimulated with B. pseudomallei or LPS for 24 h in the presence of anti–IL-10R or isotype control added at
the time of stimulation. IL-1b production was quantified by ELISA. Graphs show means 6 SEM of two (C) or at least three (A and B) independent ex-
periments. *p , 0.05, **p , 0.01, ***p , 0.001 as determined by one-way (B) or two-way (A and C) ANOVA (*C57BL/6 versus BALB/c, +C57BL/6 versus
C57BL/6 Ifnar12/2), Bonferroni multiple comparison test.
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FIGURE 8. IL-12p70 is negatively regulated by type I IFN and IL-10 in B. pseudomallei– and LPS-stimulated C57BL/6 and BALB/c macrophages.
(A and B) C57BL/6, BALB/c, and C57BL/6 Ifnar12/2 BMDMs were stimulated with B. pseudomallei or LPS for the indicated times. (C) C57BL/6 and
BALB/c BMDMs were treated with 2 or 20 ng/ml IFN-b for 2 h prior to stimulation with B. pseudomallei for 24 h. (D) C57BL/6, BALB/c, and C57BL/6
Ifnar12/2 BMDMs were stimulated with B. pseudomallei or LPS for 24 h in the presence of anti–IL-10R or isotype control added at the time of stimulation.
(E) C57BL/6 and BALB/c BMDMs were stimulated with B. pseudomallei or LPS for 24 h in the presence of anti-IFNAR1, anti–IL-10R, or isotype control
added 2 h prior to stimulation. IL-12p70 production was quantified by ELISA and Il12a mRNA expression by qRT-PCR. Graphs show means 6 SEM of
two (B and D) or at least three (A, C and E) independent experiments. *p, 0.05, **p, 0.01, ***p, 0.001 as determined by two-way ANOVA (Bonferroni
multiple comparison test).
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TRIF, and that IRF3 was more activated in B. pseudomallei–stimulated
C57BL/6 macrophages, suggest that signaling events affecting the
TLR4-TRAM/TRIF-TBK1-IRF3 axis, which is critical for the in-
duction of type I IFN downstream of TLR4 (40), may be responsible
for the enhanced production of type I IFN in this strain.
Our findings demonstrating higher levels of expression of type I
IFN in C57BL/6 macrophages led us to investigate the potential
role of type I IFN in differential production of proinflammatory
cytokines and IL-10 in C57BL/6 and BALB/c macrophages. Re-
duced IL-10 production in B. pseudomallei– and LPS-stimulated
C57BL/6 Ifnar12/2 macrophages demonstrated the importance of
autocrine type I IFN in maintaining high levels of IL-10 in
C57BL/6 macrophages. This is in agreement with previous studies
of type I IFN–regulated IL-10 production in TLR4-stimulated
macrophages (11, 41, 43). However, our detailed investigation
into the mechanisms of Il10 expression in B. pseudomallei– and
LPS-stimulated macrophages clearly showed two previously
undescribed distinct waves of active Il10 transcription in C57BL/6
but not BALB/c macrophages, the second of which was com-
pletely dependent on type I IFN signaling. We additionally iden-
tified a role for autocrine type I IFN in the stabilization of the Il10
transcript. Complete absence of the type I IFN–dependent second
peak of Il10 mRNA in BALB/c macrophages and the similar level
of IL-10 production in BALB/c and C57BL/6 Ifnar12/2 macro-
phages stimulated with B. pseudomallei and LPS provide evidence
for our novel finding that type I IFN drives differential production
of IL-10 in C57BL/6 and BALB/c macrophages. This was further
supported by our microarray analysis revealing reduced expression
of several IL-10 pathway genes in B. pseudomallei–stimulated
BALB/c and C57BL/6 Ifnar12/2 macrophages relative to C57BL/6
WT. Thus, although our data suggest that BALB/c macrophages
retain responsiveness to type I IFN, we show that the autocrine type
I IFN–mediated feed-forward loop, critical for the maintenance of
IL-10 production in TLR4-stimulated C57BL/6 macrophages (11,
41, 43), is absent in BALB/c macrophages. Furthermore, the similar
levels of IL-10 production in C57BL/6 and BALB/c macrophages
stimulated with LPS in the presence of IFN-b suggest that the low
level of type I IFN production, as opposed to deficient responsive-
ness to type I IFN, is a key contributing factor to the reduced levels
of IL-10 production observed in BALB/c macrophages.
To date, the mechanisms of IL-10 regulation by type I IFN are
incompletely understood. In accordance with the literature (35, 47–
51), we show in the present study that IL-10 production by
C57BL/6 macrophages in response to TLR ligation required both
p38 and ERK1/2 activation, although BALB/c macrophages
showed less of a requirement for ERK1/2 activation. Our further
findings that inhibition of ERK1/2 signaling also has no effect on
IL-10 production in macrophages from C57BL/6 Ifnar12/2 mice,
and that type I IFN can directly induce ERK1/2 phosphorylation,
indicate that ERK1/2 is an important factor in the regulation of IL-10
by type I IFN. In accordance with this, we show prolonged induction
of Il10 mRNA expression to be dependent on ERK1/2 but not p38
activation.
It has been reported that type I IFN requires the production of IL-27
to optimally enhance IL-10 production in C57BL/6 mouse macro-
phages stimulated with LPS (43). In the present study, we found no
role for IL-27 signaling in the production of IL-10 by LPS-
stimulated macrophages or the enhancement of IL-10 by IFN-b
treatment, although IL-27 production itself was dependent on type I
IFN signaling. Our findings thus differ from those of Iyer et al. (43)
regarding the ability of IL-27 to induce IL-10 production in C57BL/
6 macrophages, perhaps due to differences in BMDM culture or
laboratory conditions. However, our results are consistent with
previous reports that resting and TLR-stimulated murine macro-
phages are unresponsive to IL-27 (16, 44) and that IL-27 does not
regulate IL-10 production in M. tuberculosis–infected macrophages
(16). Our findings therefore demonstrate that differential production
of IL-10 in C57BL/6 and BALB/c macrophages is due to a type I
IFN–dependent but IL-27–independent mechanism.
The assessment of IL-10–deficient C57BL/6 and BALB/c mac-
rophages showed that the differential production of TNF-a, IL-12,
and IL-1b in Pam3CSK4-stimulated cells was largely attributable to
IL-10. In contrast, only differential TNF-a production was explained
by IL-10 in B. pseudomallei– and LPS-stimulated C57BL/6 and
BALB/c macrophages. IL-1b has previously been reported to be
suppressed by type I IFN in macrophages (14, 16, 42). In the ab-
sence of type I IFN signaling, we observed an increase in C57BL/6
macrophage IL-1b production to the level of BALB/c macrophages.
In keeping with previous reports (14, 16, 42), negative regulation of
IL-1b by type I IFN was retained in the absence of IL-10. Indeed, in
the absence of both IL-10 and type I IFN signaling, IL-1b pro-
duction from C57BL/6 Ifnar12/2 macrophages was higher than that
of anti–IL-10R-treated BALB/c macrophages. Thus, C57BL/6
macrophages have a high capacity to produce IL-1b when these
two inhibitory loops are removed.
Whereas type I IFN has been shown to negatively regulate
macrophage production of TNF-a and IL-1b via mechanisms that
are predominantly or only partially dependent on IL-10, respec-
tively (14, 16), it has been reported that type I IFN can both
positively and negatively regulate IL-12 production in vitro (15–19).
Furthermore, the role for IL-10 in the regulation of IL-12 by type I
IFN is not fully understood and may depend on the context (15–17).
Despite our finding that treatment with exogenous IFN-b can sup-
press B. pseudomallei–induced IL-12 production, IL-12p70 pro-
duction was not enhanced in C57BL/6 Ifnar12/2 macrophages
compared with C57BL/6 WT macrophages, even in the presence of
anti–IL-10R mAb. We postulated that the failure of C57BL/6
Ifnar12/2 macrophages to produce high levels of IL-12 was due
to the absence of tonic type I IFN signaling, reported to be required
for optimal IL-12 production in innate cells (18). Indeed, blockade
of type I IFN signaling with the anti-IFNAR1 Ab only 2 h prior to
stimulation showed an increase in IL-12p70 protein in C57BL/6
macrophages when IL-10 signaling was concomitantly blocked.
The levels of IL-12p70 in C57BL/6 macrophages were similar to
those observed in BALB/c macrophages when type I IFN and IL-10
signaling were simultaneously blocked. Collectively, our data show
that differential production and function of TLR-induced type I IFN
accounts for the differential production of IL-12p70 and IL-1b in
C57BL/6 and BALB/c macrophages.
In this study, we demonstrate distinct profiles of pro- and anti-
inflammatory cytokine production in C57BL/6 and BALB/c
macrophages and provide mechanisms to account for these differ-
ences. C57BL/6 macrophages, in response to TLR4 ligation, produced
higher levels of type I IFN accompanied by increased induction of type
I IFN–inducible genes and STAT1 activation, as compared with
BALB/c macrophages. Type I IFN was found to induce increased and
sustained Il10 mRNA expression via an ERK1/2-dependent pathway,
demonstrating the importance of temporal regulation of cytokine gene
expression. Additionally, type I IFN increased Il10 mRNA stability.
Collectively, these effects of type I IFN resulted in the increased IL-10
protein production observed in C57BL/6 macrophages. Type I IFN
regulated IL-12p70 and IL-1b production via IL-10–dependent and
IL-10–independent mechanisms, with both accounting for the differ-
ential production of these proinflammatory cytokines by C57BL/6
and BALB/c macrophages. This work highlights the complex role
of type I IFN in the regulation of innate immune responses, and it
further suggests that the extent of type I IFN–mediated activity may
differ according to the genetic background of the host. Our findings
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emphasize the fact that the C57BL/6 genetic strain of mouse,
commonly used in immunological studies, may not reflect the true
breadth of immunoregulatory mechanisms operating in TLR-
stimulated macrophages, or in broader immunological contexts,
and they support the dissection of complex molecular mecha-
nisms of cytokine gene regulation in model systems.
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SUPPLEMENTARY FIGURE 2. Reduced IL-12p70 and IL-1β production in LPS and B. 
pseudomallei stimulated C57BL/6 macrophages is not fully accounted for by IL-10 
production. C57BL/6 WT, BALB/c WT, C57BL/6 Il10-/- and BALB/c Il10-/- BMDMs were 
stimulated with Bps, LPS or Pam3CSK4 for 24 h. IL-12p70 (A), TNF-α (B) and IL-1β (C) 
levels were determined by ELISA. Graphs show means ±SEM of 3 - 4 independent 
experiments.*p<0.05, **p<0.01, ***p<0.001 as determined by two-way ANOVA (Bonferroni’s 
multiple comparison test).
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SUPPLEMENTARY FIGURE 3. IL-27 does not regulate IL-10 in C57BL/6, BALB/c or C57BL/6 Ifnar1-/- macrophages
stimulated with B. pseudomallei or LPS. (A, B) C57BL/6, BALB/c, C57BL/6 Ifnar1-/- and C57BL/6 Il27ra-/- BMDMs 
were stimulated with Bps or LPS for the indicated times. Statistics were determined by two-way ANOVA (Bonferroni’s
multiple comparison test) and show significance of (A) *C57BL/6 vs. BALB/c or +C57BL/6 vs. C57BL/6 Ifnar1-/- or (B) 
C57BL/6 vs. C57BL/6 Il27ra-/- for each time-point. (C) C57BL/6 and C57BL/6 Il27ra-/- BMDMs were stimulated for 24 h
with LPS in the presence or absence of 2 h pre-incubation with IFN-β. Statistics compare LPS alone to LPS with 2 or 
20 ng/ml IFN-β for *C57BL/6 or +C57BL/6 Il27ra-/- BMDMs as determined by two-way ANOVA (Bonferroni’s multiple 
comparison test). (D) C57BL/6, BALB/c and C57BL/6 Ifnar1-/- BMDMs were stimulated for 24 h with LPS in the presence 
or absence of 2 h pre-incubation with IL-27. (E) C57BL/6, BALB/c and C57BL/6 Ifnar1-/- BMDMs were stimulated with 
Bps or LPS for 24 h. (F) C57BL/6 Il10-/- and BALB/c Il10-/- BMDMs were stimulated with Bps or LPS for 24 h in the 
presence of anti-IFNAR1 or isotype control added 2 h prior to stimulation. Statistics were determined by two-way ANOVA 
(*) (Bonferroni’s multiple comparison test) or Student’s t-test (+). Cytokine levels in supernatants were determined by 
ELISA. Graphs show means ±SEM of 2-3 independent experiments. *p<0.05, **p<0.01, ***p<0.001
Supplementary Table 1
Genes and related log FC associated with IPA canonical payhways
Genes in the Interferon Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
G1P2 N/A 0.29
IFI35 1.33 0.61
IFIT1 2.53 2.77
IFIT3 N/A 1.33
IFITM2 0.58 N/A
IFNB1 N/A -0.92
IFNGR2 0.62 0.92
IFNγRα N/A 1.66
IRF9 N/A 0.41
NF-κBp65 N/A 0.33
OAS1 0.94 0.60
PIAS1 0.82 0.79
STAT1 1.01 0.55
STAT2 0.86 0.54
TAP1 1.22 0.72
TYK2 0.79 N/A
Genes in the JAK/Stat Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
c-FOS N/A 1.99
c-JUN 2.03 N/A
CEBPÎ² N/A 0.69
CIS N/A -1.22
GNAQ 0.78 N/A
KRAS N/A -1.60
MRAS N/A -1.70
NFKB2 2.97 3.51
PIAS1 0.82 0.79
PIAS3 -0.92 -0.56
PIK3CD 1.56 1.90
PIK3CG 1.10 N/A
RELA N/A 0.33
RRAS2 N/A -3.44
SOCS4 1.39 N/A
STAT1 1.01 0.55
STAT2 0.86 0.54
STAT3 1.76 1.39
STAT4 2.47 1.72
TYK2 0.79 N/A
Genes in the Activation of IRF by Cytosolic Pattern Recognition Receptors network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
ADAR1 1.21 0.55
c-Jun 2.03 N/A
CD-40 N/A 2.84
DAI N/A 0.66
DDX58 1.24 N/A
DHX58 1.52 0.91
IFNB1 N/A -0.92
IKBKB N/A 0.93
IKBKE N/A 0.85
IL-10 N/A 3.29
IRF-7 N/A 0.65
IRF9 N/A 0.41
ISG-15 N/A 0.29
ISG-54 1.10 1.13
MAP2K4 1.30 1.08
NFKB2 2.97 3.51
NFKBIA N/A 0.21
p300/CBP N/A 0.94
p65NFκB N/A 0.33
STAT1 1.01 0.55
STAT2 0.86 0.54
TANK N/A 0.56
TNFα N/A -0.14
Genes in the Role of JAK1, JAK2 and TYK2 in Interferon Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
IFNB1 N/A -0.92
IFNGR1 N/A 1.66
IFNGR2 0.62 0.92
NFKB2 2.97 3.51
RELA N/A 0.33
STAT1 1.01 0.55
STAT2 0.86 0.54
STAT3 1.76 1.39
TYK2 0.79 N/A
Genes in the Role of PKR in Interferon Induction and Antiviral Response network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
APAF-1 1.26 0.64
BID 0.47 0.77
CASP8 N/A 0.88
CASP9 N/A -0.29
FcγRI N/A 1.24
IFNβ N/A -0.92
IKBKB N/A 0.93
IKBKE N/A 0.85
MAP2K3 0.73 0.27
NFKB2 2.97 3.51
NFKBIA N/A 0.21
p38MAPK N/A -0.77
RELA N/A 0.33
STAT1 1.01 0.55
TNF-α N/A -0.14
TNFR1 1.44 1.23
TRAF2 N/A 0.42
Genes in the Type I Diabetes Mellitus Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
APAF1 1.26 0.64
BID 0.47 0.77
CASP8 N/A 0.88
CASP9 N/A -0.29
CD86 1.97 1.40
CPE N/A -1.28
FAS N/A 5.19
HLA-A -3.94 -10.48
HLA-DMA N/A -0.87
HLA-DQB1 N/A 6.63
HLA-DRA -5.16 -5.58
HLA-E 0.54 N/A
IFNγR1 N/A 1.66
IFNγR2 0.62 0.92
IKBKB N/A 0.93
IKBKE N/A 0.85
IL12A N/A -4.40
MAP2K3 0.73 0.27
MAP2K4 1.30 1.08
MAPK14 N/A -0.77
MYD88 1.16 0.54
NFKB2 2.97 3.51
NFKBIA N/A 0.21
PIAS1 0.82 0.79
RELA N/A 0.33
SOCS4 1.39 N/A
STAT1 1.01 0.55
TNF-α N/A -0.14
TNFRSF1A 1.44 1.23
TNFRSF1B N/A 0.62
TRAF2 N/A 0.42
Genes in the Antigen Presentation Pathway network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
CALR N/A -0.47
CLIP 1.28 0.45
HLA-A -3.94 -10.48
HLA-DMA N/A -0.87
HLA-DRA -5.16 -5.58
HLA-E 0.54 N/A
LMP2 N/A 5.03
LMPX N/A 1.43
MHCI-β 0.76 N/A
NLRC5 1.56 1.06
TAP1 1.22 0.72
TAP2 N/A 0.39
TPN 1.66 1.53
Genes in the Dendritic Cell Maturation network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
ATF4 N/A 4.43
B2M 0.76 N/A
CD40 N/A 2.84
CD86 1.97 1.40
CREBBP N/A 0.94
FCGR1A N/A 1.24
FCGR2A -0.24 -0.24
FCGR3A/FCGR3B 1.69 1.41
FSCN1 N/A -0.99
GM-CSF N/A -3.41
HLA-A -3.94 -10.48
HLA-DMA N/A -0.87
HLA-DQB1 N/A 6.63
HLA-DRA -5.16 -5.58
IFNB1 N/A -0.92
IKBKB N/A 0.93
IKBKE N/A 0.85
IL-10 N/A 3.29
IL-15 N/A 0.87
IL-23p19 N/A -1.30
IL12A N/A -4.40
IL1A N/A -1.29
IL1RN N/A 1.07
LTB -2.19 -3.45
MAP2K4 1.30 1.08
MAPK14 N/A -0.77
MYD88 1.16 0.54
NFKBIA N/A 0.21
NFκBp52 2.97 3.51
PIK3CD 1.56 1.90
PIK3CG 1.10 N/A
PLCB2 2.63 1.69
PLCL2 1.03 N/A
RELA N/A 0.33
STAT1 1.01 0.55
STAT2 0.86 0.54
STAT4 2.47 1.72
TLR2 N/A -0.14
TLR4 N/A 1.61
TNF-α N/A -0.14
TNFRSF1A 1.44 1.23
TNFRSF1B N/A 0.62
Genes in the OX40 Signaling Pathway network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
B2M 0.76 N/A
H2-K2/H2-Q9 N/A 1.88
H2-M2 N/A 0.56
H2-Q8 -1.35 -1.56
H2-T10 4.93 4.97
H2-T24 N/A -0.32
HLA-A -3.94 -10.48
HLA-DMA N/A -0.87
HLA-DQB1 N/A 6.63
HLA-DRA -5.16 -5.58
HLA-E 0.54 N/A
JUN 2.03 N/A
MAP2K4 1.30 1.08
NFKB2 2.97 3.51
NFKBIA N/A 0.21
RELA N/A 0.33
TRAF2 N/A 0.42
Genes in the Pancreatic Adenocarcinoma Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
CASP9 N/A -0.29
CDKN1B 1.87 N/A
CyclinD1 N/A 2.14
E2F2 N/A 0.18
E2F6 N/A -1.40
HMOX1 N/A 1.05
K-Ras N/A -1.60
MAP2K4 1.30 1.08
MDM2 1.19 0.70
MMP9 -1.49 -2.80
NFKB2 2.97 3.51
PIK3CD 1.56 1.90
PIK3CG 1.10 N/A
PLD1 N/A 0.51
RELA N/A 0.33
SMAD2 2.04 1.85
SMAD3 1.34 N/A
STAT1 1.01 0.55
STAT3 1.76 1.39
SURVIVIN N/A -0.83
TGFβR2 N/A -1.56
TYK2 0.79 N/A
VEGFA 1.54 N/A
Genes in the phagosome maturation network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
ATP6V0A1 N/A -0.32
ATP6V0B 1.05 0.59
ATP6V0E2 N/A -2.46
B2M 0.76 N/A
CALR N/A -0.47
DCTN4 N/A 0.78
Dync1i2 N/A 0.97
DYNLRB1 0.83 0.44
HLA-A -3.94 -10.48
HLA-DRA -5.16 -5.58
LAMP2 0.55 0.81
NAPB N/A 0.01
PRDX2 N/A 0.61
RAB7B 1.17 4.11
TAP1 1.22 0.72
TUBB2B -0.55 -2.36
TUBG1 N/A -1.09
VAMP3 0.90 N/A
VPS33A -0.43 -0.74
VPS37B 1.24 N/A
VTI1A N/A 1.34
VTI1B N/A 2.89
YKT6 0.88 N/A
Genes in the Death Receptor Signaling network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
APAF1 1.26 0.64
BID 0.47 0.77
CASP9 N/A -0.29
CASP8 N/A 0.88
DAXX 1.17 0.81
DR6 N/A -0.47
FAS N/A 5.19
HtrA2 N/A -0.57
IKBKB N/A 0.93
IKBKE N/A 0.85
MAP2K4 1.30 1.08
NFKB2 2.97 3.51
NFKBIA N/A 0.21
PARP12 N/A 0.68
PARP14 0.96 0.59
PARP2 N/A 0.18
PARP3 N/A 2.00
PARP4 N/A 0.71
PARP8 N/A 3.78
PARP9 N/A 0.72
RELA N/A 0.33
TANK N/A 0.56
TNF-R2 N/A 0.62
TNF-α N/A -0.14
TNFRSF1A 1.44 1.23
TRAF2 N/A 0.42
ZC3HAV1 N/A 0.35
Genes in the Crosstalk between Dendritic Cells and Natural Killer Cells network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
CD40 N/A 2.84
CD69 N/A 0.61
CD86 1.97 1.40
CSF2RB N/A 0.65
Fas N/A 5.19
FSCN1 N/A -0.99
GM-CSF N/A -3.41
HLA-A -3.94 -10.48
HLA-DRA -5.16 -5.58
HLA-E 0.54 N/A
IFNB1 N/A -0.92
IL-15 N/A 0.87
IL12A N/A -4.40
IL15RA 1.67 1.10
IL3RA 1.58 1.65
LFA-1 N/A -1.00
LTB -2.19 -3.45
MICB 1.07 N/A
Nectin2 N/A -0.92
NFKB2 2.97 3.51
RELA N/A 0.33
TLR4 N/A 1.61
TLR7 N/A 0.63
TNF-α N/A -0.14
TNFR2 N/A 0.62
Genes in the Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
ADAMTS4 N/A -2.48
ATF4 N/A 4.43
c-Fos N/A 1.99
c-Jun 2.03 N/A
C5AR N/A 0.25
CEBPB N/A 0.69
CREBBP N/A 0.94
CyclinD1 N/A 2.14
DAMM1 1.66 N/A
DVL N/A -1.11
FcγRIIIa 1.69 1.41
FCγR1 N/A 1.24
FN1 N/A -0.77
FZD7 N/A 1.02
GM-CSF N/A -3.41
GNAQ 0.78 N/A
IKBKB N/A 0.93
IKBKE N/A 0.85
IL-10 N/A 3.29
IL-15 N/A 0.87
IL-6R N/A 1.00
IL1A N/A -1.29
IL1RN N/A 1.07
IRAK3 N/A 0.23
KRAS N/A -1.60
LTB -2.19 -3.45
MAP2K3 0.73 0.27
MAP2K4 1.30 1.08
MCP-1 N/A 0.61
MRAS N/A -1.70
MYD88 1.16 0.54
NFATC3 N/A 0.67
NFKBIA N/A 0.21
NLK N/A -1.21
OSM N/A -0.64
p38 MAPKα N/A -0.77
PDGFB N/A 0.78
PIK3CD 1.56 1.90
PIK3CG 1.10 N/A
PLCB2 2.63 1.69
PLCL2 1.03 N/A
PPP3R1 N/A -0.37
PRKD3 N/A -0.94
RANTES N/A 0.22
RELA N/A 0.33
RRAS2 N/A -3.44
RYK N/A -3.28
Src N/A -0.80
STAT3 1.76 1.39
TCF4 0.85 1.00
TLR2 N/A -0.14
TLR4 N/A 1.61
TLR6 N/A -0.53
TLR7 N/A 0.63
TNF N/A -0.14
TNFRSF1A 1.44 1.23
TNFRSF1B N/A 0.62
TRAF1 N/A 0.40
TRAF2 N/A 0.42
VCAM-1 N/A -1.31
VEGFA 1.54 N/A
Genes in the Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
C1QB N/A 3.17
C3 N/A 0.35
C5aR N/A 0.25
Casp1 N/A 0.48
CSF2 N/A -3.41
DECTIN-1 N/A -0.89
DECTIN-2 N/A 0.52
IFNB1 N/A -0.92
IL-10 N/A 3.29
IL12A N/A -4.40
IL1A N/A -1.29
IRF-7 N/A 0.65
MAP2K4 1.30 1.08
MYD88 1.16 0.54
NFKB2 2.97 3.51
NOD1 N/A 1.42
NOD2 -1.50 -1.79
OAS1 0.94 0.60
OAS3 1.46 1.01
OSM N/A -0.64
PIK3CD 1.56 1.90
PIK3CG 1.10 N/A
PRKD3 N/A -0.94
PTX3 N/A 4.34
RANTES N/A 0.22
RELA N/A 0.33
RIG-1 1.24 N/A
TLR2 N/A -0.14
TLR4 N/A 1.61
TLR6 N/A -0.53
TLR7 N/A 0.63
TNF-α N/A -0.14
Genes in the Communication between Innate and Adaptive Immune Cells network
Symbol Log FC C57BL/6-Bps vs. BALB/c-BPS (3h) Log FC C57BL/6-Bps vs. BALB/c-BPS (6h)
B2M 0.76 N/A
CCL3L3 N/A 0.25
CD40 N/A 2.84
CD86 1.97 1.40
CD8B -0.76 -1.76
GM-CSF N/A -3.41
HLA-A -3.94 -10.48
HLA-DRA -5.16 -5.58
HLA-E 0.54 N/A
IFNB1 N/A -0.92
IL-10 N/A 3.29
IL-15 N/A 0.87
IL12A N/A -4.40
IL1A N/A -1.29
IL1RN N/A 1.07
IP-10 N/A 3.64
RANTES N/A 0.22
TLR2 N/A -0.14
TLR4 N/A 1.61
TLR6 N/A -0.53
TLR7 N/A 0.63
TNF-α N/A -0.14
